GNE-495 is a potent and selective MAP4K4 inhibitor with an IC 50 of 3.7 nM. In Vitro GNE-495 is a potent and selective MAP4K4 inhibitor with efficacy in retinal angiogenesis. GNE-495 shows the best balance of MAP4K4 inhibition, permeability, microsomal stability, and cellular potency. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo GNE-495 is administered intraperitoneally to neonatal mouse pups at high doses: 25 and 50 mg/kg. GNE-495 shows good in vivo profile in all species tested, with low clearances, moderate terminal half-lives, and reasonable oral exposure levels (F=37-47%) . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:MAP4K4 3.7 nM (IC 50 )